CANF
Price
$4.25
Change
+$0.21 (+5.20%)
Updated
Feb 5, 04:57 PM (EDT)
Capitalization
6M
Intraday BUY SELL Signals
TBPH
Price
$19.58
Change
-$0.51 (-2.54%)
Updated
Feb 5 closing price
Capitalization
992.17M
24 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CANF vs TBPH

Header iconCANF vs TBPH Comparison
Open Charts CANF vs TBPHBanner chart's image
Can-Fite Biopharma
Price$4.25
Change+$0.21 (+5.20%)
Volume$450
Capitalization6M
Theravance Biopharma
Price$19.58
Change-$0.51 (-2.54%)
Volume$352.13K
Capitalization992.17M
CANF vs TBPH Comparison Chart in %
CANF
Daily Signal:
Gain/Loss:
TBPH
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CANF vs. TBPH commentary
Feb 06, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANF is a Hold and TBPH is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 06, 2026
Stock price -- (CANF: $4.04 vs. TBPH: $20.09)
Brand notoriety: CANF and TBPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CANF: 6% vs. TBPH: 115%
Market capitalization -- CANF: $5.58M vs. TBPH: $1.02B
CANF [@Biotechnology] is valued at $5.58M. TBPH’s [@Biotechnology] market capitalization is $1.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $119.38B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CANF’s FA Score shows that 1 FA rating(s) are green whileTBPH’s FA Score has 0 green FA rating(s).

  • CANF’s FA Score: 1 green, 4 red.
  • TBPH’s FA Score: 0 green, 5 red.
According to our system of comparison, TBPH is a better buy in the long-term than CANF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CANF’s TA Score shows that 4 TA indicator(s) are bullish while TBPH’s TA Score has 3 bullish TA indicator(s).

  • CANF’s TA Score: 4 bullish, 3 bearish.
  • TBPH’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CANF is a better buy in the short-term than TBPH.

Price Growth

CANF (@Biotechnology) experienced а -8.80% price change this week, while TBPH (@Biotechnology) price change was +5.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.10%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was +28.24%.

Reported Earning Dates

TBPH is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (-7.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TBPH($992M) has a higher market cap than CANF($6M). TBPH YTD gains are higher at: 7.376 vs. CANF (1.000). TBPH has higher annual earnings (EBITDA): 53.1M vs. CANF (-8.91M). TBPH has more cash in the bank: 330M vs. CANF (995K). CANF has less debt than TBPH: CANF (90K) vs TBPH (44.6M). TBPH has higher revenues than CANF: TBPH (80.3M) vs CANF (560K).
CANFTBPHCANF / TBPH
Capitalization6M992M1%
EBITDA-8.91M53.1M-17%
Gain YTD1.0007.37614%
P/E RatioN/A34.35-
Revenue560K80.3M1%
Total Cash995K330M0%
Total Debt90K44.6M0%
FUNDAMENTALS RATINGS
CANF vs TBPH: Fundamental Ratings
CANF
TBPH
OUTLOOK RATING
1..100
282
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
79
Overvalued
PROFIT vs RISK RATING
1..100
10085
SMR RATING
1..100
10055
PRICE GROWTH RATING
1..100
9338
P/E GROWTH RATING
1..100
10084
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CANF's Valuation (17) in the Biotechnology industry is somewhat better than the same rating for TBPH (79) in the Pharmaceuticals Other industry. This means that CANF’s stock grew somewhat faster than TBPH’s over the last 12 months.

TBPH's Profit vs Risk Rating (85) in the Pharmaceuticals Other industry is in the same range as CANF (100) in the Biotechnology industry. This means that TBPH’s stock grew similarly to CANF’s over the last 12 months.

TBPH's SMR Rating (55) in the Pharmaceuticals Other industry is somewhat better than the same rating for CANF (100) in the Biotechnology industry. This means that TBPH’s stock grew somewhat faster than CANF’s over the last 12 months.

TBPH's Price Growth Rating (38) in the Pharmaceuticals Other industry is somewhat better than the same rating for CANF (93) in the Biotechnology industry. This means that TBPH’s stock grew somewhat faster than CANF’s over the last 12 months.

TBPH's P/E Growth Rating (84) in the Pharmaceuticals Other industry is in the same range as CANF (100) in the Biotechnology industry. This means that TBPH’s stock grew similarly to CANF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CANFTBPH
RSI
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 2 days ago
53%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
65%
MACD
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 14 days ago
75%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 11 days ago
69%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
58%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
CANF
Daily Signal:
Gain/Loss:
TBPH
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EQNAX23.270.07
+0.30%
MFS Equity Income A
JNBSX10.65-0.02
-0.19%
JPMorgan Income Builder I
BWLCX24.47-0.07
-0.29%
American Beacon Man Lg Cp Value C
RLSIX14.69-0.10
-0.68%
RiverPark Long/Short Opportunity Instl
MADCX32.00-0.24
-0.74%
BlackRock Emerging Mkts Instl

CANF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CANF has been closely correlated with ACET. These tickers have moved in lockstep 87% of the time. This A.I.-generated data suggests there is a high statistical probability that if CANF jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
-0.25%
ACET - CANF
87%
Closely correlated
-3.51%
STRO - CANF
87%
Closely correlated
+0.40%
PMN - CANF
87%
Closely correlated
-1.57%
ATOS - CANF
86%
Closely correlated
-4.34%
PHGE - CANF
86%
Closely correlated
-7.36%
More

TBPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, TBPH has been loosely correlated with VTYX. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if TBPH jumps, then VTYX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TBPH
1D Price
Change %
TBPH100%
+0.50%
VTYX - TBPH
63%
Loosely correlated
-0.29%
ACET - TBPH
59%
Loosely correlated
-3.51%
ARWR - TBPH
58%
Loosely correlated
-5.66%
PMN - TBPH
58%
Loosely correlated
-1.57%
CANF - TBPH
57%
Loosely correlated
-0.25%
More